



FULL DISCLOSURE POLICY AFFECTING CME ACTIVITIES

Clinical Center Grand Rounds

Lipsett Amphitheater

Bethesda, Maryland

November 28, 2012

As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Speakers are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

SPEAKERS NAME AND LECTURE TITLES

March Ghany, M.D.

The Yin and Yang of Chronic Liver Diseases: New and Emerging Therapies for HCV-A Death Knell for HCV

Yaron Rotman, M.D.

Fatty Liver Disease: Update and Insights Into a Rising Epidemic

No speaker has indicated that they have any financial interests or relationships with a commercial entity whose products or services are relevant to the content of their presentations.

No planner has indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:

Name & Lecture Title

Yaron Rotman, M.D.

“The Yin and Yang of Chronic Liver Diseases:
New and Emerging Therapies for HCV-A Death Knell for HCV”

Marc Ghany, M.D.

“Fatty Liver Disease: Update and Insights Into a Rising Epidemic”

Product

Vitamin E, Pioglitazone, Metformin

**Asunaprevir, Daclatasvir, Sofosbuvir, Simeprevir,
Alosporivir, Numerous Others...**

EVALUATION FORM

Clinical Center Grand Rounds at the National Institutes of Health

November 28, 2012

Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:

1 - None or Not at all 2 - Very little 3 - Moderately 4 - Considerably 5 - Completely N/A - Not applicable

Speaker: Marc Ghany, M.D.

Objective:

A. Rating of Objectives and Activity

1. Please rate the attainment of objectives:
 - a. Define options and alternatives that will guide clinical practice 1 2 3 4 5 N/A
 - b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances 1 2 3 4 5 N/A
 - c. Analyze information and opportunities to increase and improve collaboration between investigators 1 2 3 4 5 N/A
2. The overall quality of the instructional process was an asset to the activity: 1 2 3 4 5 N/A
3. To what extent did participation in this activity enhance your professional effectiveness? 1 2 3 4 5 N/A
4. Will you change your practice in any way as a result of attending this activity? 1 2 3 4 5 N/A
5. Did you perceive any commercial bias? Use the following criteria to judge?
 - a) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. ___No ___Yes
If no, please specify: _____
 - b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. ___No ___Yes
If no, please specify: _____
 - c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. ___No ___Yes
If no, please specify: _____

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?

3. Do you have additional comments to enhance the utility or impact of the activity?

4. May we contact you in several week's time with a very brief survey to assess the usefulness of this CME activity? ___Yes ___No If yes, please provide your email: _____

EVALUATION FORM

Clinical Center Grand Rounds at the National Institutes of Health

November 28, 2012

Please complete the Continuing Medical Education Questionnaire. To indicate your answers, use the rating scale that is shown by circling the number that represents your answer.

Scale:

1 - None or Not at all 2 - Very little 3 - Moderately 4 - Considerably 5 - Completely N/A - Not applicable

Speaker: Yaron Rotman, M.D.

Objective: To recognize the clinical impact of fatty liver disease. Outline recent advances in understanding the pathophysiology of fatty liver disease. Identify current and future therapeutic options for the disease.

A. Rating of Objectives and Activity

5. Please rate the attainment of objectives:

- a. Define options and alternatives that will guide clinical practice 1 2 3 4 5 N/A
- b. Evaluate practical information about clinical research principles based on state-of-the-art information about scientific discovery and clinical advances 1 2 3 4 5 N/A
- c. Analyze information and opportunities to increase and improve collaboration between investigators 1 2 3 4 5 N/A

6. The overall quality of the instructional process was an asset to the activity: 1 2 3 4 5 N/A

7. To what extent did participation in this activity enhance your professional effectiveness? 1 2 3 4 5 N/A

4. Will you change your practice in any way as a result of attending this activity? 1 2 3 4 5 N/A

5. Did you perceive any commercial bias? Use the following criteria to judge?

b) The content presented was balanced, evidence-based, demonstrated scientific rigor, and was without commercial bias. ___No ___Yes
If no, please specify: _____

b) I was informed about the existence and resolution of relevant financial relationships/conflicts of interests of planners and presenters prior to the presentation. ___No ___Yes
If no, please specify: _____

c) Speakers who discussed off-label, investigational, or alternative uses of products, devices, or techniques disclosed this in their presentation. ___No ___Yes
If no, please specify: _____

B. Comments:

1. What comments or suggestions do you have for the faculty presenter(s)?

2. Are there any other speakers or new topics you would like to have covered in this or a related activity?

3. Do you have additional comments to enhance the utility or impact of the activity?

8. May we contact you in several week's time with a very brief survey to assess the usefulness of this CME activity? ___Yes ___No If yes, please provide your email: _____